Multiple Myeloma | Norton Healthcare

Indication: Multiple Myeloma

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

Sub-indication: Multiple Myeloma

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Janssen Research & Development

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.